Center for Childhood Cancer Research Seminar

“Developing the Next Generation of AML Therapy through Trials, Tribulations, and Collaboration”

Todd Cooper, D.O.
Professor of Pediatrics
Inpatient Medical Director
Director, Leukemia Lymphoma Program
Director, High Risk Leukemia Program
Cancer and Blood Disorders Center
Seattle Children’s Hospital
University of Washington School of Medicine

Date: January 23, 2020
Time: 12 p.m. – 1:00 p.m.
Location: Children’s Hospital of Philadelphia, Colket Translational Research Building (CTRB), 4040

Lunch Provided

Lecture Learning Objectives

Upon completion of this lecture/session, participants should be able to:

1. Understand historical perspective of childhood AML therapy
2. Understand pediatric development of CPX-351
3. Understand development of risk stratification for Phase 3 study AAML1831

Accreditation Statement
The Children's Hospital of Philadelphia is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

AMA Credit Designation Statement
The Children's Hospital of Philadelphia designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Dr. Todd Cooper, has signed the CHOP CME Disclosure of Relevant Financial Relationships Form and has affirmed that neither she/nor her spouse/partner/family member has/had any relevant financial relationships/financial affiliations with a commercial interest within the past 12 months related directly or indirectly to the content of this lecture that may pose a potential conflict of interest within the context of this presentation.

Stephen Hunger, MD (Course Director) and Monica S. Williams, MS (CME Planner) have disclosed that neither they, nor their spouse/partner have any relevant financial relationships with commercial interest.